Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Effectiveness of Remdesivir, Lopinavir/Ritonavir, and Favipiravir for COVID-19 Treatment: A Systematic Review
Windi Fresha Qomara, Delya Nur Primanissa, Salma Hasni Amalia, et al.
International Journal of General Medicine (2021) Vol. Volume 14, pp. 8557-8571
Open Access | Times Cited: 53

Showing 1-25 of 53 citing articles:

A concise review of mushrooms antiviral and immunomodulatory properties that may combat against COVID-19
Karuppusamy Arunachalam, Sreeja Puthanpura Sasidharan, Xuefei Yang
Food Chemistry Advances (2022) Vol. 1, pp. 100023-100023
Open Access | Times Cited: 44
Economic evaluation of COVID-19 vaccination: A systematic review
Auliasari Utami, Farida Rendrayani, Qisty A Khoiry, et al.
Journal of Global Health (2023) Vol. 13
Open Access | Times Cited: 29
Therapeutic dilemmas in addressing SARS-CoV-2 infection: Favipiravir versus Remdesivir
Paul Andrei Negru, Andrei-Flavius Radu, Cosmin Mihai Vesa, et al.
Biomedicine & Pharmacotherapy (2022) Vol. 147, pp. 112700-112700
Open Access | Times Cited: 27
Obesity and COVID-19: Mechanistic Insights From Adipose Tissue
Lili Yu, Xiaoying Zhang, Sarah Ye, et al.
The Journal of Clinical Endocrinology & Metabolism (2022) Vol. 107, Iss. 7, pp. 1799-1811
Open Access | Times Cited: 27
The Potential of Nanobodies for COVID-19 Diagnostics and Therapeutics
Dhaneshree Bestinee Naidoo, Anil A. Chuturgoon
Molecular Diagnosis & Therapy (2023) Vol. 27, Iss. 2, pp. 193-226
Open Access | Times Cited: 19
Inhibitors of SARS-CoV-2 Main Protease (Mpro) as Anti-Coronavirus Agents
Agnieszka Zagórska, Anna Czopek, Monika Fryc, et al.
Biomolecules (2024) Vol. 14, Iss. 7, pp. 797-797
Open Access | Times Cited: 6
Comparison of greenness and blueness assessments for analytical methods used in the analysis of ritonavir, favipiravir, and molnupiravir: Applications in different matrices
Christine K. Nessim, Abdulsalam Ashkar, Bahga M. El-Zablaawy, et al.
Microchemical Journal (2025), pp. 113165-113165
Closed Access
Involvement of virus infections and antiviral agents in schizophrenia
Alejandro Borrego-Ruiz, Juan J. Borrego
Psychological Medicine (2025) Vol. 55
Closed Access
Real-World Experience of the Comparative Effectiveness and Safety of Molnupiravir and Nirmatrelvir/Ritonavir in High-Risk Patients with COVID-19 in a Community Setting
Yoshikazu Mutoh, Takumi Umemura, Takeshi Nishikawa, et al.
Viruses (2023) Vol. 15, Iss. 3, pp. 811-811
Open Access | Times Cited: 12
Discovery of Small Molecules Targeting the Frameshifting Element RNA in SARS-CoV-2 Viral Genome
Mo Yang, Feyisola P. Olatunji, Curran A. Rhodes, et al.
ACS Medicinal Chemistry Letters (2023) Vol. 14, Iss. 6, pp. 757-765
Closed Access | Times Cited: 12
A review on drug repurposing in COVID-19: from antiviral drugs to herbal alternatives
Abas Sezer, Mervisa Halilović-Alihodžić, Annissa Rachel Vanwieren, et al.
Journal of Genetic Engineering and Biotechnology (2022) Vol. 20, Iss. 1, pp. 78-78
Open Access | Times Cited: 17
Targeting viral proteins for restraining SARS-CoV-2: focusing lens on viral proteins beyond spike for discovering new drug targets
Tao Yang, Si Chun Wang, Linyan Ye, et al.
Expert Opinion on Drug Discovery (2023) Vol. 18, Iss. 3, pp. 247-268
Closed Access | Times Cited: 8
Targeting the Complement–Sphingolipid System in COVID-19 and Gaucher Diseases: Evidence for a New Treatment Strategy
Vyoma Snehal Trivedi, Albert Frank Magnusen, Reena Rani, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 22, pp. 14340-14340
Open Access | Times Cited: 11
Will the Use of Pharmacogenetics Improve Treatment Efficiency in COVID-19?
Beata Franczyk, Jacek Rysz, Jarosław Miłoński, et al.
Pharmaceuticals (2022) Vol. 15, Iss. 6, pp. 739-739
Open Access | Times Cited: 10
Potential limitations in systematic review studies assessing the effect of the main intervention for treatment/therapy of COVID-19 patients: An overview
Mahsa Mohseni, Hosein Ameri, Morteza Arab‐Zozani
Frontiers in Medicine (2022) Vol. 9
Open Access | Times Cited: 9
Paxlovid reduces the 28-day mortality of patients with COVID-19: a retrospective cohort study
Kaican Zong, Xu Li, Chun Huai Luo, et al.
BMC Infectious Diseases (2024) Vol. 24, Iss. 1
Open Access | Times Cited: 1
Drug-Induced Acute Pancreatitis in Hospitalized COVID-19 Patients
Daniel Paramythiotis, Eleni Karlafti, Kalliopi Veroplidou, et al.
Diagnostics (2023) Vol. 13, Iss. 8, pp. 1398-1398
Open Access | Times Cited: 4
Role of macrophage polarization in cancer progression and their association with COVID-19 severity
Abhimanyu Thakur, Rumpa Banerjee, Sudha Thakur, et al.
Cancer Insight (2023)
Open Access | Times Cited: 4
Development of a colorimetric assay for quantification of favipiravir in human serum using ferrihydrite
Yukiko Moriiwa, Natsu Oyama, Ryo Otsuka, et al.
Talanta (2022) Vol. 252, pp. 123827-123827
Closed Access | Times Cited: 7
Molecular docking analysis of ten plant products for the inhibition of spike glycoprotein and prospective use as anti-COVID compounds
Medhat Farag, Aslam Pathan, Nawaf Aldoij
Annals of Phytomedicine An International Journal (2022) Vol. 11, Iss. 2
Open Access | Times Cited: 7
Evaluation of Global Post-Outbreak COVID-19 Treatment Interventions: A Systematic Review and Bibliometric Analysis of Randomized Controlled Trials
Mohammed Alfaqeeh, Neily Zakiyah, Auliya A. Suwantika, et al.
Journal of Multidisciplinary Healthcare (2023) Vol. Volume 16, pp. 4193-4209
Open Access | Times Cited: 3
Plant-derived Ren's oligopeptide has antiviral effects on influenza virus and SARS-CoV-2
Chengzhi Yu, Yayu Huang, Xin Ren, et al.
Frontiers in Veterinary Science (2023) Vol. 9
Open Access | Times Cited: 2
Current state-of-the-art review of nanotechnology-based therapeutics for viral pandemics: Special attention to COVID-19
Marjan Motiei, Lucian A. Lucia, Tomáš Sáha, et al.
Nanotechnology Reviews (2023) Vol. 12, Iss. 1
Open Access | Times Cited: 2
N-acetylcysteine as adjuvant therapy for hospitalized Covid-19 patients: A single-center prospective cohort study.
Siamak Afaghi, Negin Moghimi, Nasser Malekpour Alamdari, et al.
PubMed (2023) Vol. 14, Iss. 3, pp. 543-552
Closed Access | Times Cited: 2
The possible techniques that used to improve the bioavailablity, pharmacological activity, solubility and permeability of anti-viral drugs: Insight for COVID-19 antiviral drugs
Ghassan Mudher Hashim, Ghaidaa S. Hameed, Dalya Basil Hanna
Al Mustansiriyah Journal of Pharmaceutical Sciences (2023) Vol. 23, Iss. 3, pp. 231-249
Open Access | Times Cited: 2
Page 1 - Next Page

Scroll to top